Healthcare Videos

Reclassifying Cannabis? Implications for Recreational/Medical Marijuana Use, Research, Drug Policy

The Harvard‑hosted webinar examined the federal effort to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. Panelists traced the historical attempts—legislative bills, lawsuits, and recent executive actions—highlighting President Trump’s 2025 executive order and Attorney General Merrick Garland’s pending rule, which would finally recognize a "currently accepted medical use" for marijuana. Key insights centered on the statutory criteria for scheduling: medical utility, abuse potential, and safety. A 2022 reinterpretation by HHS broadened the definition of medical use to include state‑level legalization and physician prescribing, overturning the earlier FDA‑approval standard that had blocked rescheduling. Experts noted that this shift, coupled with growing clinical experience and emerging research, underpins the push toward Schedule III. Panelists offered vivid examples: Dr. Peter Ginspoon contrasted cannabis’s relative safety with tobacco and alcohol, arguing that criminalization is a war‑on‑drugs artifact. Lawyer Hersh Jane quantified the economic impact, noting that Schedule III would repeal IRS Code 280E, lowering costs and curbing illicit market demand. Activist Epha Taio Harvey warned that rescheduling alone won’t resolve racial disparities, emphasizing the need for broader policy reforms. The implications are profound. Schedule III status would unlock banking services, enable tax deductions, and catalyze state‑level reforms, while also reshaping international drug‑policy dialogues. For investors, clinicians, and policymakers, the move signals a transition from prohibition to regulated medical market, with potential to accelerate research, reduce stigma, and address longstanding equity concerns.